Phase I Study of Hepatitis C Virus (HCV) Entry Inhibitor (ITX 5061) in Liver Transplant Recipients With HCV Infection

Next Previous
Trial Profile

Phase I Study of Hepatitis C Virus (HCV) Entry Inhibitor (ITX 5061) in Liver Transplant Recipients With HCV Infection

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs ITX 5061 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions

    • Most Recent Events

    • 27 Jan 2017 Planned End Date changed from 1 Oct 2015 to 1 Oct 2017.
    • 27 Jan 2017 Planned primary completion date changed from 1 May 2015 to 1 May 2017.
    • 17 Nov 2014 Planned End Date changed from 1 Oct 2013 to 1 Oct 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top